Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
| 2.21 Delayed Data As of Nov 25 |  -0.02 / -0.90%Today’s Change | 1.01 Today|||52-Week Range 4.28 | -41.07% Year-to-Date |
Latest ADAP News | Press Releases
No recent news for Adaptimmune Therapeutics PLC.
Today’s Trading
| Previous close | 2.23 |
| Today’s open | 2.23 |
| Day’s range | 2.19 - 2.37 |
| Volume | 2,567 |
| Average volume (3 months) | 428,984 |
| Market cap | $385.8M |
Data as of 12:59pm ET, 11/25/2022
Growth & Valuation
| Earnings growth (last year) | -10.25% |
| Earnings growth (this year) | -542.35% |
| Earnings growth (next 5 years) | +5.60% |
| Revenue growth (last year) | +54.14% |
| P/E ratio | NM |
| Price/Sales | 95.03 |
| Price/Book | 1.79 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| WVEWAVE Life Sciences L... | +0.02 | +0.48% |
| PTGXProtagonist Therapeu... | -0.02 | -0.26% |
| HRTXHeron Therapeutics I... | +0.01 | +0.35% |
| ---- |
Data as of 1:00pm ET, 11/25/2022
Financials
| Last reporting date | November 25, 2022 |
| EPS forecast (this quarter) | -$0.25 |
| Annual revenue (last year) | $6.1M |
| Annual profit (last year) | -$158.1M |
| Net profit margin | -2,570.99% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Abingdon, Oxfordshire |
Forecasts
